Agoracom Blog Home

Posts Tagged ‘#Psilocybin’

Mota Ventures $MOTA.ca Reports Monthly Revenues of Cdn$5,141,000 for Natures Exclusive, Highest in the History of the Brand $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 8:19 AM on Wednesday, June 10th, 2020
  • Revenue for the month of May totaled Cdn$5,141,000, representing an increase of 110% compared to May 2019
  • 23,141 new customers during the month of May 2020

VANCOUVER, BC, CANADA / ACCESSWIRE / June 10, 2020 / Mota Ventures Corp. (CSE:MOTA) (FSE:1WZ1)(OTC PINK:PEMTF) (the “Company“) the Company’s subsidiary, Nature’s Exclusive, an eCommerce provider of CBD products to consumers in the United States, is pleased to announce an all-time monthly revenue record achieved during May 2020. Revenue for the month of May totaled Cdn$5,141,000, representing an increase of 110% compared to May 2019. Expenses totaled Cdn$4,992,000 for the month, representing a gross profit of Cdn$149,000 for May 2020.

The Company’s investment in customer acquisition continues to yield benefits with the brand acquiring 23,141 new customers during the month of May 2020. The Company’s strong ability to continue to acquire and retain new customers for its products continues to accelerate. As consumers continue to seek natural health product solutions, the Nature’s Exclusive brand is well positioned to offer consumers quality and convenience.

NATURE’S EXCLUSIVE CBD BRAND LEADING THE WAY

The Company’s Nature’s Exclusive brand offers a CBD hemp-oil formulation intended to provide users with the therapeutic benefits that hemp may offer. The hemp oil used in the products is derived from hemp grown and cultivated in the United States. The extraction process is designed to maintain all the beneficial qualities that hemp may offer. Nature’s Exclusive offers a range of products, which include CBD oil drops, CBD gummies, CBD pain relief cream, CBD skin serum and CBD coffee.

“I am very pleased our Nature’s Exclusive brand achieved another monthly sales record. We continued to expand in the United States, and our outlook for the second half of fiscal 2020 is very positive. We remain on track to achieve our goals for 2020 despite the recent economic turmoil,” stated Ryan Hoggan, CEO of the Company.

We encourage readers to visit www.motaventuresco.com to view our brands and sign up to our newsletter.

The Company cautions that figures for revenue, expenses and margin generated from the sale of Nature’s Exclusive products in fiscal year 2020 have not been audited, and are based on calculations prepared by management. Actual results may differ from those reported in this release once these figures have been audited. These figures were translated from US dollars into Canadian dollars using the Bank of Canada monthly average exchange rate of US$1.00:Cdn$1.397 for May 2020 and US$1.00:Cdn$1.3459 for May 2019.

About Mota Ventures Corp.

Mota Ventures is an established eCommerce, direct to consumer provider of a wide range of natural health products including CBD and psychedelic medicine products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its Nature’s Exclusive brand. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. In Germany, Verrian currently produces natural psilocybin extract capsules under the PSI GEN and PSI GEN+ brand. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS
MOTA VENTURES CORP.

Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

Mota Ventures $MOTA.ca Signs Binding Term Sheet to Acquire E-Commerce Platform Leader Unified Funding with C$93.8 Million in Consumer Transactions in 2019 $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 11:32 AM on Saturday, June 6th, 2020

June 6, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTC PINK:PEMTF) (the “Company“) is pleased to announce that it has entered into a binding term sheet (the “Term Sheet“) dated June 5, 2020 with Unified Funding LLC (“Unified“). The term sheet replaces the previous preliminary letter of intent entered into with Unified on May 21, 2020.

Ryan Hoggan, Chief Executive Officer stated “The very nature of CBD, natural health products and psychedelics unequivocally points the future of our nascent industry into digital targeting, marketing and engagement of customers who will turn to the web to learn about and acquire the right products for them. Mota has already demonstrated superior eCommerce capabilities in 2020 but this acquisition of Unified will make us a formidable presence in the space.”

Hoggan added “From a shareholder value point of view, the one thing the biggest tech companies in the world have in common – according to McKinsey – is that they are all platform-based organizations that owe much of their success to the agility with which they are able to innovate and reconfigure themselves to go after new opportunities. With this acquisition, we hope to establish a platform that will serve a growing global industry going forward.”

PLATFORM HAS FACILITATED C$364 MILLION IN TRANSACTIONS SINCE 2015, C$93.8 MILLION IN 2019

Unified is a leading eCommerce platform company established in 2015 by partners with over a decade experience in eCommerce marketing. Unified has developed a proprietary technology platform along with a CRM designed specifically for emerging, small and medium sized eCommerce businesses worldwide. To date, the platform has successfully facilitated over CDN$364,000,000 in consumer transactions, including CDN$93,800,000 in 2019 alone.

The platform generates revenue from licensing, marketing and product fulfillment fees supporting brands in the natural health products sector, including skin care, nutraceutical, essential oils and CBD. Unified brings the platform and experience needed for the Company to expand its product portfolio and brands. Integration of the platform with the Unified experienced team of professionals to run it will allow the Company to develop new products and enter new natural healthcare markets, aided significantly by Unified’s ability to closely track current trends through a global network of media partners.

Kevin Keranen, Chairman of Unified, stated “Along with a diverse team of eCommerce experts, we have built one of the most comprehensive eCommerce platforms in the natural health products sector. Our combination of technology with a full team of individuals dedicated to specific segments of the business allows us to deliver robust growth for our clients. As we look to become a part of Mota, we will be able to access the growth capital to further expand our marketing efforts and support any initiative drive by the Company in a more strategic manner.”

UNIFIED PLATFORM GOES BEYOND PRODUCT SALES

Unified provides a comprehensive suite of managed services in high-demand by its clients. These services are driven by both technology and a team of over forty United States based employees that include:

Customer Acquisition: Unified creates and executes digital marketing campaigns to acquire customers in the clients targeted demographic. By utilizing Unified’s vast marketing channels, clients are able to learn about new market trends and adapt accordingly.

Product Development: Unified is able to guide product development by utilizing intelligence generated by the millions of customer records of opt-in buyers and potential buyers. Unified has relationships with product development professionals, labs and manufacturers to create products within scope and within budget.

Supply Chain Management & Logistics: Through its partners, Unified can help manage clients supply chain to ensure on-time delivery to each customer’s doorstep and to adapt to varying levels of product demand.

Customer Service: As part of the technology platform, Unified provides real-time customer service metrics to accurately measure performance of each customer service agent, which significantly impacts the profitability of each clients business.

Profitability Analysis: Most importantly, the technology and staff at Unified are focused on profitability for each and every client. The business manages over 100 key performance indicators that have been developed through experience, which translates to higher success rates for Unified clients.

PROPOSED TRANSACTION

The Letter of Intent contemplates that the Company would acquire Unified in consideration for US$45,000,000, which will be satisfied through the issuance of common shares of the Company (the “Consideration Shares“). The Consideration Shares will be issuable at a deemed price (the “Transaction Price“) equivalent to the greater of: (i) the volume-weighted average closing price of the common shares of the Company on the Canadian Securities Exchange in the ten trading days prior to the entering into of a definitive agreement in respect of the acquisition, and (ii) Cdn$0.40.

In addition to the Consideration Shares, Unified will be entitled to receive a one-time bonus payment of US$15,000,000 (the “Bonus Payment“) in the event the Company achieves gross revenue in excess of US$15,000,000 from the Unified business in the twelve-month period following closing of the acquisition. The Bonus Payment will be payable in common shares of the Company (the “Bonus Shares“), at the Transaction Price.

The Consideration Shares, and the Bonus Shares, will be subject to terms of a thirty-six month time-release pooling arrangement, during which time they may not be transferred, assigned, pledged or otherwise traded. The shares will be released from the pooling arrangement in tranches, of which twenty percent will be released upon issuance, and the balance in six equal tranches every six months thereafter.

Completion of the proposed acquisition of Unified remains subject to a number of conditions, including, but not limited to, satisfactory completion of due diligence, negotiation of definitive documentation and the receipt of any required regulatory approvals. The acquisition cannot be completed until these conditions are satisfied and there can be no assurance that the acquisition will be completed at all.

The proposed acquisition is not expected to constitute a fundamental change for the Company, nor is it expected to result in a change of control of the Company, within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange. The Company will provide further information regarding the proposed acquisition, as that information becomes available.

This press release is available for investor discussion on the Company’s AGORACOM Discussion Forum, a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.

Figures presented in this news release were translated from US dollars into Canadian dollars using the Bank of Canada closing exchange rate on June 3, 2020 of US$1.00:Cdn$1.3504.

About Mota Ventures Corp.

Mota Ventures is an established eCommerce, direct to consumer provider of a wide range of natural health products including CBD and psychedelic medicine products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its Nature’s Exclusive brand. Within Europe, its Satavida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. In German Verrian currently produces natural psilocybin extract capsules under the PSI GEN and PSI GEN+ brand. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS

MOTA VENTURES CORP.
Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Mota Ventures $MOTA.ca Closes $20,000,000 Acquisition of European Pharmaceutical Manufacturer of Natural Psilocybin Extracts $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 7:41 AM on Tuesday, June 2nd, 2020
  • The market for psychedelic derived medicines and therapies is estimated to be as high as USD$100 Billion

VANCOUVER, BC / June 2, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTC PINK:PEMTF) (the “Company“) a leading ecommerce provider of CBD products to consumers in the United States and Europe, is pleased to announce the completion of its’ Cdn$20,000,000 acquisition (the “Transaction“) of all of the outstanding share capital of Verrian Ontario Ltd. (“Verrian“) effective June 1, 2020. Verrian is an established and well advanced European psychedelic medicine company that is focused on delivering and developing products related to addiction reduction, with a focus on alcohol and opiates.

Ryan Hoggan, CEO of the Company stated, “The massive shift towards psychedelic derived medicines is no longer in doubt and this acquisition sends a strong signal to the market that Mota Ventures intends to be a serious participant this coming decade. Unlike some companies that use psychedelics as a marketing term, this acquisition of Verrian brings Mota market ready products, world renowned addiction medicine experts, R&D facilities and a 110,000 square foot facility to make it happen. In my opinion this is the most complete psychedelic asset on the market, and therefore should immediately make Mota a market leader in the space.”

Hoggan further added, “In 2020, we have proven our e-commerce ability to acquire tens of thousands of customers and generate millions of dollars in monthly revenues from CBD sales. We intend to bring that same market expertise to bear with our psychedelics business in 2020 and far beyond.”

ACQUISTION PROVIDES MOTA WITH IMMEDIATE ENTRY INTO FAST GROWING $100 BILLION PSYCHEDELICS INDUSTRY

The market for psychedelic derived medicines and therapies is estimated to be as high as USD$100 Billion*. Over the past decade, growing societal awareness and acceptance of mental disorders and addiction as real diseases has accelerated the push for new and innovative treatments using psychedelics, including psilocybin.

As a result, psychedelic research published back in the 50s and 60s has resurfaced and once again highlighted their curative properties. Moreover, the recent legalization of Cannabis in Canada, as well as, across 33 US states for medicinal purposes, has significantly mitigated any stigma, leading to accelerated interest and investment in the psychedelics industry.

Verrian has already developed two psilocybin products that are natural psilocybin extracts, from organically cultivated mushrooms, combined with metabolism enhancing natural herbs. This is only the beginning with further products in various stages of development.

ESTABLISHED EUROPEAN PSYCHEDELIC MEDICINE COMPANY

Verrian owns and operates a 110,000 square foot pharmaceutical manufacturing facility in Radebuel, Germany. Operations within this full suite pharmaceutical manufacturing site include analytical laboratory and finished dose manufacturing, which exceed all international quality standards. The facility and equipment of Verrian have been independently appraised at Cdn$10,600,000 and include an analytical laboratory and full pharmaceutical manufacturing suite.

Verrian operates three distinct business segments:

  • Pharmaceutical Manufacturing – A portfolio of medical & wellness products
  • Phyto API – API creation from medical plants
  • Analytical Testing – European Medicine Agency Standards

PRODUCTS FOCUSED ON OPIATE ADDICTION REDUCTION

Verrian’s singular focus is rewiring the mind to overcome addiction through natural medicine. Specifically, the micro dosing of psilocybin demonstrates potential to remove the dopamine reward of addictive substances, potentially diminishing the desire for addictive substances, thereby reducing or eliminating the need for the addictive substance.

To date Verrian has developed two psilocybin products: PSI GEN and PSI GEN+. These Psilocybin products are focused on opiate addiction reduction. As natural psilocybin extracts, from organically cultivated mushrooms, combined with metabolism enhancing natural herbs, they are ideal for individuals commencing micro-dosing and capable of being combined with additional anti-addiction therapies.

All of Verrian’s compounds are derived from organic, glyphosate free naturally occurring plants, grown specifically for its own purposes.

GOALS AND VISION

In addition to the facility and equipment outlined above, Verrian has invested approximately Cdn$2,400,000 in clinical trial design and development of proprietary formulations for its psilocybin trademarked PSI-GEN products, and cannabis products, including trademarked CBDaily and CBNight.

Verrian’s world renowned addiction medicine experts are moving ahead to develop new potential treatments for therapy, with rigorous clinical research. Once EU GMP and narcotics handling recertification are secured, capabilities will extend to: specialty pharmaceutical formulations; and psilocybin refinement and production for micro dosing.

In consideration for the acquisition of all of the outstanding share capital of Verrian, the Company has issued 54,347,826 common shares (the “Consideration Shares“) to the existing shareholders of Verrian at a deemed price of $0.368 per Consideration Share. 50,543,478 of the Consideration Shares are subject to terms of a thirty-six month time release pooling arrangement, during which time they may not be transferred, assigned, pledged or otherwise traded. The Consideration Shares will be released from the pooling arrangement in tranches, of which ten-percent will be released after four months, fifteen percent after six months, and the balance in five equal tranches every six months thereafter. In addition to the Consideration Shares, upon closing of the Transaction, the Company has arranged for repayment of $150,000 of existing shareholder loans of Verrian, and will arrange for repayment of the balance of $950,000 within sixty days of closing.

The Company is at arms-length from Verrian, and each of its shareholders. The Transaction does not constitute a fundamental change for the Company, nor has it resulted in a change of control of the Company, within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange. In connection with completion of the Transaction, the Company has paid a finders’ fee of 5,434,783 common shares to certain arms’-length parties who have assisted in facilitating the Transaction. The Company has also paid an administrative fee of 1,086,957 common shares of the Company to a consultant who assisted with the Transaction.

We encourage shareholders and prospective investors to visit the Company’s AGORACOM Discussion Forum, a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.

About Mota Ventures Corp.

Mota Ventures is an established natural health products company focused in the CBD and psychedelic medicine sectors. Through its powerful eCommerce business, Mota is a leading is a direct-to-consumer provider of a wide range of natural health products throughout the United States and Europe. In the United States, the Company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the United States through its Nature’s Exclusive brand. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom.

Through its German-based Verrian operation, Mota is researching and testing the efficacy and application of natural psilocybin products for the treatment of opioid and other life altering addictions. Mota is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD and other natural health products.

ON BEHALF OF THE BOARD OF DIRECTORS
MOTA VENTURES CORP.

Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com